The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD

The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD

Barbara P Yawn1, Ibrahim Raphiou2, Judith S Hurley3, Anand A Dalal21Olmsted Medical Center, University of Minnesota, Rochester, Minnesota, USA; 2GlaxoSmithKline, Research Triangle Park, North Carolina, USA; 3Hurley Consulting, Placitas, New Mexico, USAAbstract: Exacerbations contribute significantly...

Full description

Bibliographic Details
Main Authors:	Barbara P Yawn, Ibrahim Raphiou, Judith S Hurley, et al
Format:	Article
Language:	English
Published:	Dove Medical Press 2010-06-01
Series:	International Journal of COPD
Online Access:	http://www.dovepress.com/the-role-of-fluticasone-propionatesalmeterol-combination-therapy-in-pr-a4535

Similar Items

Effectiveness of Indacaterol-Glycopyrronium in preventing COPD exacerbations in comparison to Salmeterol-Fluticasone
by: Shamim Ahmed, et al.
Published: (2022-02-01)

Cost-effectiveness of combination fluticasone propionate&ndash;salmeterol 250/50 &mu;g versus salmeterol in severe COPD patients
by: An, et al.
Published: (2010-06-01)

Effects of Salmeterol and Fluticasone Propionate Combination versus Fluticasone Propionate on Airway Function and Eosinophilic Inflammation in Mild Asthma
by: Makoto Hoshino, et al.
Published: (2009-01-01)

Onset of action of indacaterol in patients with COPD: Comparison with salbutamol and salmeterol-fluticasone
by: Beatrix Balint, et al.
Published: (2010-09-01)

Retracted: Biochemical Behaviours of Salmeterol/Fluticasone Propionate in Treating Asthma and Chronic Obstructive Pulmonary Diseases (COPD)
by: Emergency Medicine International
Published: (2024-01-01)

Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy
by: Moretz C, et al.
Published: (2020-10-01)

Low-dose Fluticasone Propionate in Combination With Salmeterol in Patients With Chronic Obstructive Pulmonary Disease
by: Hideki Yasui, et al.
Published: (2018-05-01)

Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease.
by: Barnes, N, et al.
Published: (2006)

Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease
by: An, et al.
Published: (2010-12-01)

The efficacy and safety of fluticasone propionate/formoterol compared with fluticasone propionate/salmeterol in treating pediatric asthma: a systematic review and meta-analysis
by: Renzheng Guan, et al.
Published: (2020-10-01)

Microencapsulation of Fluticasone Propionate and Salmeterol Xinafoate in Modified Chitosan Microparticles for Release Optimization
by: Nina Maria Ainali, et al.
Published: (2020-08-01)

Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast: a randomised controlled trial investigating the effects on airway inflammation in asthma.
by: Pavord, I, et al.
Published: (2007)

Salmeterol/fluticasone propionate (50/250 µg) combination is superior to double dose fluticasone (500 µg) for the treatment of symptomatic moderate asthma
by: K-C Bergmann, et al.
Published: (2004-01-01)

Effects of Salmeterol Xinafoate and Fluticasone Propionate on Immunological Activation of Human Cultured Mast Cells
by: Hirotomo Akabane, et al.
Published: (2006-01-01)

Clinical and economic outcomes for patients initiating fluticasone propionate/salmeterol combination therapy (250/50 mcg) versus anticholinergics in a comorbid COPD/depression population
by: Dalal AA, et al.
Published: (2012-01-01)

Non-inferiority efficacy comparison of mometasone furoate/formoterol versus fluticasone propionate/salmeterol combination therapies in subjects with persistent asthma
by: Bernstein David I, et al.
Published: (2010-12-01)

Efficacy and onset of action of mometasone furoate/formoterol and fluticasone propionate/salmeterol combination treatment in subjects with persistent asthma
by: Bernstein David I, et al.
Published: (2011-12-01)

Umeclidinium/Vilanterol Compared with Fluticasone Propionate/Salmeterol, Budesonide/Formoterol, and Tiotropium as Initial Maintenance Therapy in Patients with COPD Who Have High Costs and Comorbidities
by: Kalhan R, et al.
Published: (2021-04-01)

The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD
by: Anzueto AR, et al.
Published: (2017-05-01)

Anti-inflammatory effects of salmeterol/fluticasone propionate 50/250 mcg combination therapy in Japanese patients with chronic obstructive pulmonary disease
by: Asai K, et al.
Published: (2015-04-01)

Role of the fixed combination of fluticasone and salmeterol in adult Chinese patients with asthma and COPD
by: Gao J, et al.
Published: (2015-04-01)

Novel Fluticasone Propionate and Salmeterol Fixed-Dose Combination Nano-Encapsulated Particles Using Polyamide Based on L-Lysine
by: Mohammad H. Alyami, et al.
Published: (2022-03-01)

Managing moderate-to-severe paediatric asthma: a scoping review of the efficacy and safety of fluticasone propionate/salmeterol
by: Sira Nanthapisal, et al.
Published: (2023-12-01)

Fluticasone propionate-salmeterol versus inhaled corticosteroids plus montelukast: outcomes study in pediatric patients with asthma
by: Stanford RH, et al.
Published: (2012-12-01)

Combined fluticasone propionate and salmeterol reduces RSV infection more effectively than either of them alone in allergen-sensitized mice
by: Ledford Dennis, et al.
Published: (2006-05-01)

Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study
by: Moretz C, et al.
Published: (2019-08-01)

The comparative effectiveness of initiating fluticasone/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database study
by: Jones R, et al.
Published: (2017-08-01)

Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study
by: Antonio R. Anzueto, et al.
Published: (2018-06-01)

Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study
by: Jadwiga A. Wedzicha, et al.
Published: (2019-01-01)

Fluticasone propionate and increased risk of pneumonia in COPD: is it PAFR-dependent?
by: Sohal SS
Published: (2017-12-01)

Comparison of fluticasone propionate and budesonide on COPD macrophage and neutrophil function
by: Belchamber KBR, et al.
Published: (2018-09-01)

Patients with Asthma Prescribed Once-Daily Fluticasone Furoate/Vilanterol or Twice-Daily Fluticasone Propionate/Salmeterol as Maintenance Treatment: Analysis from a Claims Database
by: Ryo Atsuta, et al.
Published: (2018-10-01)

New developed spectrophotometric method for simultaneous determination of salmeterol xinafoate and fluticasone propionate in bulk powder and Seritide® diskus inhalation
by: Ahmed Samir, et al.
Published: (2012-12-01)

Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD
by: Martyn R. Partridge, et al.
Published: (2009-08-01)

Value of adding a polyvalent mechanical bacterial lysate to therapy of COPD patients under regular treatment with salmeterol/fluticasone
by: Mario Cazzola, et al.
Published: (2009-04-01)

Asthma control using fluticasone propionate/salmeterol in Asian and non-Asian populations: a post hoc analysis of the GOAL study
by: Jean Bousquet, et al.
Published: (2017-04-01)

The EFFECT trial: evaluating exacerbations, biomarkers, and safety outcomes with two dose levels of fluticasone propionate/formoterol in COPD
by: Papi A, et al.
Published: (2015-11-01)

The Efficacy, Tolerance and Acceptance of a New Fixed-Dose Salmeterol and Fluticasone Propionate Dry-Powder Inhaler—Salflumix Easyhaler<sup>®</sup> in COPD Patients in the Daily Clinical Practice
by: Zbigniew Doniec, et al.
Published: (2022-11-01)

Effect of salmeterol/fluticasone combination on the dynamic changes of lung mechanics in mechanically ventilated COPD patients: a prospective pilot study
by: Chen WC, et al.
Published: (2016-01-01)

Superiority of tiotropium plus olodaterol in comparison with salmeterol plus fluticasone
by: Tamura T, et al.
Published: (2016-11-01)